GATA3 and triple-negative breast carcinoma: EZH2 inhibitors remove this repressive mark, opening GATA3 enhancers, upregulating GATA3 expression, and synergizing with AKT inhibitors to induce differentiation and apoptosis in triple-negative breast cancer (TNBC) cells (Fig. 3B) [179].